Abstract
Background: Invasive lobular carcinoma (ILC) represents 5–15% of all BC, and has a different biological behaviour from invasive ductal carcinoma (IDC). Clinical trials (CT) in luminal metastatic BC (mBC) have demonstrated the benefits of hormonal therapy (HT) + iCDK 4/6 combinations in survival. Data on the magnitude of clinical benefit in ILC mBC is scarce. The aim of this study is to evaluate the response of ILC mBC to HT+iCDK4/6 combinations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
